This announcement replaces the original announcement released on 10 January 2012 at 18.22 (RNS No: 3416V).
One of the Non-Executive Director's interests in the Ordinary shares of GlaxoSmithKline plc, indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 10 January 2012.
Save as disclosed above, all other details remain unchanged. The full amended text is shown below.
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary shares and American Depositary Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2011:
GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award- Annual Dividend Reinvestment
Non-Executive Director |
No. of Ordinary Shares |
Average Price (£) |
No. of ADSs |
Average Price ($) |
Sir Christopher Gent |
3,072.732 |
14.70 |
|
|
Prof Sir Roy Anderson |
408.069 |
14.70 |
|
|
Dr Stephanie Burns |
|
|
361.105 |
45.53 |
Ms Stacey Cartwright |
3.865 |
14.70 |
|
|
Mr Lawrence Culp |
|
|
1,133.685 |
45.53 |
Sir Crispin Davis |
2,536.065 |
14.70 |
|
|
Ms Judy Lewent |
|
|
1.998 |
45.53 |
Sir Deryck Maughan |
|
|
1,033.536 |
45.53 |
Mr James Murdoch |
467.973* |
14.70 |
|
|
Dr Daniel Podolsky |
|
|
623.023 |
45.53 |
Mr Tom de Swaan |
612.754 |
14.70 |
|
|
Sir Robert Wilson |
710.997 |
14.70 |
|
|
The Company and the Non-Executive Directors were informed of these allocations on
10 January 2012.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary